MRVI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

49.03M

-13.31%

-0.070

+16.95%

50.60M

+8%

-0.053

-33.86%

49.41M

+4.26%

-0.052

-34.55%

Estimates Revision

The market is revising Downward the revenue expectations for Maravai LifeSciences Holdings, Inc. (MRVI) for FY2025, with the revenue forecasts being adjusted by -0.04% over the past three months. During the same period, the stock price has changed by 34.19%.

Revenue Estimates for FY2025

Revise Downward

-0.04%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.46%

In Past 3 Month

Stock Price

Go Up

+34.19%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast MRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRVI is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 3.650

Low

4.00

Averages

4.50

High

5.00

Current: 3.650

Low

4.00

Averages

4.50

High

5.00

Wells Fargo

Brandon Couillard

maintain

2025-12-15

New

Reason

Wells Fargo

Brandon Couillard

Price Target

2025-12-15

New

maintain

Reason

Wells Fargo analyst Brandon Couillard raised the firm's price target on Maravai Lifesciences to $4.50 from $4 and keeps an Overweight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Stifel

Buy

downgrade

$5 -> $4

2025-11-07

Reason

Stifel

Price Target

$5 -> $4

2025-11-07

downgrade

Buy

Reason

Stifel lowered the firm's price target on Maravai Lifesciences to $4 from $5 and keeps a Buy rating on the shares. Maravai posted a Q3 miss with revenue of $42M coming in below the $50M consensus view, the analyst tells investors in a research note. The firm added that Maravai looks "fairly washed out" at the $2-$3 level, but with a new management team and low visibility, the shares are appropriate for only the intrepid right now.

Craig-Hallum

Buy

downgrade

$10 -> $5

2025-08-12

Reason

Craig-Hallum

Price Target

$10 -> $5

2025-08-12

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on Maravai Lifesciences to $5 from $10 and keeps a Buy rating on the shares. The company announced a new plan to turn things around. The company plans to cut $50M in annual spending through headcount reductions and spending cuts across all departments. With changes occurring gradually over the next 12 months, management plans to decrease the expense run rate through FY26, the firm notes.

RBC Capital

Outperform

NULL

downgrade

$7 -> $5

2025-08-12

Reason

RBC Capital

Price Target

$7 -> $5

2025-08-12

downgrade

Outperform

NULL

Reason

RBC Capital lowered the firm's price target on Maravai Lifesciences to $5 from $7 and keeps an Outperform rating on the shares after its Q2 earnings miss. With the new management in place and FY25 guidance suspended however, Maravai is on a path to rationalizing its cost structure, starting with $50M in cost actions with aims to return to adjusted EBITDA positive by the second half of FY26, the analyst tells investors in a research note.

Baird

Catherine Ramsey Schulte

Neutral

downgrade

$3 -> $2

2025-05-13

Reason

Baird

Catherine Ramsey Schulte

Price Target

$3 -> $2

2025-05-13

downgrade

Neutral

Reason

Baird analyst Catherine Ramsey Schulte lowered the firm's price target on Maravai Lifesciences to $2 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where revenue beat and guidance is maintained for 2025.

Craig-Hallum

Matt Hewitt

Buy

downgrade

$12 -> $10

2025-05-13

Reason

Craig-Hallum

Matt Hewitt

Price Target

$12 -> $10

2025-05-13

downgrade

Buy

Reason

Craig-Hallum analyst Matt Hewitt lowered the firm's price target on Maravai Lifesciences to $10 from $12 and keeps a Buy rating on the shares following quarterly results. The firm noted that investors should take a closer look at the company, as they are well-positioned to benefit from the industry's shift toward repatriation of pharma manufacturing and the FDA's new AI/modeling initiative-driving demand for the company's specialized products and services.

Valuation Metrics

The current forward P/E ratio for Maravai LifeSciences Holdings Inc (MRVI.O) is -15.98, compared to its 5-year average forward P/E of 1165.29. For a more detailed relative valuation and DCF analysis to assess Maravai LifeSciences Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

1165.29

Current PE

-15.98

Overvalued PE

6016.41

Undervalued PE

-3685.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.78

Current EV/EBITDA

-412.39

Overvalued EV/EBITDA

81.87

Undervalued EV/EBITDA

-103.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.30

Current PS

2.66

Overvalued PS

6.00

Undervalued PS

2.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MRVI News & Events

Events Timeline

No data

News

5.0

12-10NASDAQ.COM

Insider Buying Update for Wednesday, October 12: AVTR, MRVI

2.0

12-10NASDAQ.COM

Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers

7.0

10-28Globenewswire

Reminder: Bragar Eagel & Squire, P.C. Ongoing Investigation for Maravai Long-Term Shareholders

People Also Watch

Frequently Asked Questions

What is Maravai LifeSciences Holdings Inc (MRVI) stock price today?

The current price of MRVI is 3.65 USD — it has increased 1.39 % in the last trading day.

What is Maravai LifeSciences Holdings Inc (MRVI)'s business?

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

What is the price predicton of MRVI Stock?

What is Maravai LifeSciences Holdings Inc (MRVI)'s revenue for the last quarter?

Maravai LifeSciences Holdings Inc revenue for the last quarter amounts to 41.63M USD, decreased -39.69 % YoY.

What is Maravai LifeSciences Holdings Inc (MRVI)'s earnings per share (EPS) for the last quarter?

Maravai LifeSciences Holdings Inc. EPS for the last quarter amounts to -0.18 USD, decreased -73.91 % YoY.

What changes have occurred in the market's expectations for Maravai LifeSciences Holdings Inc (MRVI)'s fundamentals?

How many employees does Maravai LifeSciences Holdings Inc (MRVI). have?

Maravai LifeSciences Holdings Inc (MRVI) has 570 emplpoyees as of December 15 2025.

What is Maravai LifeSciences Holdings Inc (MRVI) market cap?

Today MRVI has the market capitalization of 920.54M USD.